Regeneron Pharmaceuticals Inc (REGN)
Liquidity ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 4.73 | 5.28 | 5.44 | 5.27 | 5.69 | 5.18 | 5.45 | 5.45 | 5.06 | 5.36 | 5.12 | 4.76 | 3.56 | 3.71 | 3.57 | 3.12 | 3.63 | 3.89 | 2.12 | 4.21 |
| Quick ratio | 3.86 | 4.34 | 4.43 | 4.40 | 4.82 | 4.31 | 4.53 | 4.54 | 4.16 | 4.37 | 4.20 | 3.95 | 2.98 | 3.03 | 2.92 | 2.39 | 2.48 | 2.81 | 1.49 | 3.18 |
| Cash ratio | 2.28 | 2.68 | 2.80 | 2.94 | 3.17 | 2.75 | 2.88 | 2.89 | 2.46 | 2.44 | 2.49 | 2.34 | 1.45 | 1.56 | 1.05 | 1.09 | 1.33 | 1.29 | 0.85 | 1.95 |
Regeneron Pharmaceuticals Inc has shown strong liquidity position based on its current ratio, which measures the company's ability to cover its short-term obligations with its current assets. The current ratio has been consistently above 2 in the past few years, ranging from 3.12 to 5.69 as of December 31, 2024. This indicates that the company has more than enough current assets to meet its current liabilities, demonstrating a healthy liquidity position.
Additionally, the quick ratio, which excludes inventory from current assets to provide a more conservative measure of liquidity, has also been well above 1, ranging from 2.39 to 4.82 as of December 31, 2024. This suggests that Regeneron Pharmaceuticals Inc can quickly cover its short-term liabilities using its most liquid assets, such as cash and accounts receivable.
Furthermore, the cash ratio, which specifically measures the company's ability to cover its current liabilities with cash and cash equivalents, has improved over the years, ranging from 1.09 to 3.17 as of December 31, 2024. This indicates that the company has a solid ability to meet its immediate obligations with its cash reserves.
Overall, Regeneron Pharmaceuticals Inc's liquidity ratios reflect a healthy financial position, with its current, quick, and cash ratios all consistently above industry averages, showcasing the company's strong liquidity management and ability to meet its short-term obligations effectively.
See also:
Regeneron Pharmaceuticals Inc Liquidity Ratios (Quarterly Data)
Additional liquidity measure
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash conversion cycle | days | 419.96 | 457.32 | 433.34 | 401.03 | 412.24 | 539.30 | 530.97 | 540.59 | 584.01 | 520.13 | 489.29 | 419.14 | 358.99 | 563.64 | 647.61 | 716.01 | 510.15 | 543.43 | 441.07 | 404.23 |
The cash conversion cycle (CCC) of Regeneron Pharmaceuticals Inc has shown fluctuations over the periods provided in the data. Initially, in the first quarter of 2020, the CCC stood at 404.23 days, indicating that the company took approximately 404 days to convert its investments in inventory and other resources into cash flows from sales.
The CCC increased in subsequent quarters, reaching its peak at 716.01 days by the first quarter of 2021, which suggests Regeneron Pharmaceuticals was taking a significantly longer time to convert its resources into cash during that period.
Subsequently, there was a downward trend in the CCC, with improvements seen in the last quarters of the data series. By the end of December 2024, the CCC had reduced to 419.96 days, signifying that the company had been able to manage its cash flow cycle more efficiently.
Overall, the trend indicates that Regeneron Pharmaceuticals Inc had some challenges in efficiently managing its cash conversion cycle in the past, but efforts were made to improve this metric, resulting in a more optimized cash conversion process by the end of the data period. It is important to continue monitoring this metric to ensure sustained efficiency in managing the company's working capital and cash flows.